

Clinacyn®

Clindamycin
Capsule

Description

Clindamycin is a lincosamide antibiotic. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as the Gram-negative anaerobes.

Indications and Uses

Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of *streptococci*, *pneumococci* and *staphylococci*. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.

Infections caused by Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection.

Infections caused by *Streptococci*: Serious respiratory tract infections; serious skin and soft tissue infections.

Infections caused by *Staphylococci*: Serious respiratory tract infections; serious skin and soft tissue infections.

Infections caused by *Pneumococci*: Serious respiratory tract infections.

Dosage and Administration

Adults

Serious infections: 150 to 300 mg every 6

hours.

More severe infections: 300 to 450 mg every 6 hours.

Pediatric Patients

Serious infections: 8 to 16 mg/kg/day divided into three or four equal doses.

More severe infections: 16 to 20 mg/kg/day divided into three or four equal doses.

To avoid the possibility of esophageal irritation, Clindamycin capsules should be taken with a full glass of water. In clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with Clindamycin capsules.

In cases of β -hemolytic streptococcal infections, treatment should be continued for at least 10 days.

Contraindications

Clindamycin is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Adverse Reactions

The following reactions have been reported with the use of clindamycin:

Abdominal pain, pseudomembranous colitis, esophagitis, nausea, vomiting and diarrhea.

Pruritus, vaginitis, and rare instances of exfoliative dermatitis have been reported.

Rare instances of polyarthritis have been reported.

Precautions

Clindamycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Clindamycin should be prescribed with caution in atopic individuals.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Drug Interaction

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Antagonism has been demonstrated between Clindamycin and erythromycin in vitro. Because of possible clinical significance, these two drugs should not be administered concurrently.

Use in Pregnancy and Lactation

Pregnancy category B. There is no adequate and well-controlled study in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.

Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/ml. It is not recommended to use Clindamycin for lactating mother.

Use in Pediatric Patients

When Clindamycin is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.

Storage Condition

Keep in a cool and dry place. Protect from light.

Commercial Pack

Clinacyn® 150 Capsule: Box containing 30 capsules in 3 X 10's blister strips. Each capsule contains Clindamycin Hydrochloride BP equivalent to Clindamycin 150 mg.

Clinacyn® 300 Capsule: Box containing 30 capsules in 3 X 10's blister strips. Each capsule contains Clindamycin Hydrochloride BP equivalent to Clindamycin 300 mg.



Manufactured by

BEXIMCO PHARMACEUTICALS LTD.

TONGI, BANGLADESH BL 8477 110613

© Clinacyn is a registered trademark of Beximco Pharmaceuticals Ltd.



105 mm x 160 mm FS

105 mm x 160 mm FS